Escin

DB15907InvestigationalSmall molecule

Escin is an anti-inflammatory and vasoconstrictive agent indicated to treat minor muscle and joint trauma. Sodium aescinate is under investigation in clinical trials for its potential to treat cerebral conditions, including NCT04247659 (studying the relationship between asymmetric vascular sign of cortex and prognosis in massive cerebral infarction) and NCT05263167 (aimed...

Mechanism: Pharmacologically active on Glucocorticoid receptor and Hyaluronidase enzymes
Curator reviewed
Formula / weight: C₁₁₀H₁₇₂O₄₈ · 2262.538 g/mol (avg)
Also known as: Aescin · Escin mixture
Code names: 229-880-6

Resolves to

Compound

UNIIRUU8G67GQMCAS6805-41-0

Clinical / RWD

RxNorm4065

Structure

InChIKeyYFESOSRPNPYODN-RSMWSHJLSA-NSMILES

[H][C@@]1(O[C@H]2[C@H](O)[C@@H](O[C@]3([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@]([H])(OC3CC[C@@]4(C)C(CC[C@]5(C)C4CC=C4C6CC(C)(C)[C@@H](OC(=O)C(\C)=C/C)[C@H](OC(C)=O)[C@]6(CO)[C@H](O)C[C@@]54C)[C@@]3(C)CO)O[C@@H]2C(O)=O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O.[H][C@@]1(O[C@H]2[C@H](O)[C@@H](O[C@]3([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@]([H])(OC3CC[C@@]4(C)C(CC[C@]5(C)C4CC=C4C6CC(C)(C)[C@@H](OC(=O)C(\C)=C\C)[C@H](OC(C)=O)[C@]6(CO)[C@H](O)C[C@@]54C)[C@@]3(C)CO)O[C@@H]2C(O)=O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O

Targets

P04150NR3C1P12931SRC

What you can answer from here — as of August 31, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

19Structured indicationsCondition, population, route and combination as fields, not prose

4ContraindicationsEach with its own population and attribute set

20Marketed productsAcross 2 countries and 5 labellers

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Escin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account